摘要
背景:新的异二聚体双结合位点乙酰胆碱酯酶抑制剂的设计是开发具有扩大药理作用的新型抗胆碱酯酶药物的主要目标。多目标化合物通常是通过混合分子与已知的两个或多个药理学分子结合来设计的,以使其与选定的分子靶点发生相互作用。方法:检测所有化合物对人AChE/BChE的抑制作用。用Ellman法测定抑制动力学和IC 50值。为了预测新化合物的被动血脑透过率,对平行人工膜渗透法进行了改进。为了预测与Hache/hBChE结合的新杂种的结合模式,进行了对接研究。结果:本研究介绍了一系列他克林-香豆素和他克林-喹啉类化合物的设计、合成和评价,发现它们对CHs有潜在的抑制作用,对血脑屏障有潜在的抑制作用。结论:他克林-喹啉杂合7a对hBChE活性最高(IC 50=0.97μ),对Hache活性最高(IC 50=0.32μ)。动力学和分子模型研究表明,7d为混合型AChE抑制剂(Ki=1.69μ),7a为混合型BChE抑制剂(Ki=1.09mol)。此外,杂交5d和7c可以穿透CNS。
关键词: 阿尔茨海默病,香豆素,乙酰胆碱酯酶抑制剂,合成,胆碱酯酶,对接。
Current Alzheimer Research
Title:Tacrine-coumarin and Tacrine-7-chloroquinoline Hybrids with Thiourea Linkers: Cholinesterase Inhibition Properties, Kinetic Study, Molecular Docking and Permeability Assay for Blood-brain Barrier
Volume: 15 Issue: 12
关键词: 阿尔茨海默病,香豆素,乙酰胆碱酯酶抑制剂,合成,胆碱酯酶,对接。
摘要: Background: The design of new heterodimeric dual binding site acetylcholinesterase inhibitors constitutes the main goal-directed to the development of new anticholinesterase agents with the expanded pharmacological profile. Multi-target compounds are usually designed by combining in a hybrid molecule with two or more pharmacophoric moieties that are known to enable interaction with the selected molecular targets.
Methods: All compounds were tested for their inhibitory activity on human AChE/BChE. The Ellman´s method was used to determine inhibition kinetics and IC50 values. In order to predict passive bloodbrain penetration of novel compounds, modification of the parallel artificial membrane permeation assay has been used. Docking studies were performed in order to predict the binding modes of new hybrids with hAChE/ hBChE respectively.
Results: In this study, we described the design, synthesis, and evaluation of series tacrine-coumarin and tacrine-quinoline compounds which were found to show potential inhibition of ChEs and penetration of the blood-brain barrier.
Conclusion: Tacrine-quinoline hybrids 7a exhibited the highest activity towards hBChE (IC50 = 0.97 µmol) and 7d towards hAChE (IC50 = 0.32 µmol). Kinetic and molecular modelling studies revealed that 7d was a mixed-type AChE inhibitor (Ki = 1.69 µmol) and 7a was a mixed-type BChE inhibitor (Ki = 1.09 µmol). Moreover, hybrid 5d and 7c could penetrate the CNS.
Export Options
About this article
Cite this article as:
Tacrine-coumarin and Tacrine-7-chloroquinoline Hybrids with Thiourea Linkers: Cholinesterase Inhibition Properties, Kinetic Study, Molecular Docking and Permeability Assay for Blood-brain Barrier, Current Alzheimer Research 2018; 15 (12) . https://dx.doi.org/10.2174/1567205015666180711110750
DOI https://dx.doi.org/10.2174/1567205015666180711110750 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiological Role of Mitochondrial Potassium Channels and their Modulation by Drugs
Current Medicinal Chemistry A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery
Current Drug Metabolism Recent Advances in the Rationale Design of GPER Ligands
Current Medicinal Chemistry Editorial [Hot Topic: ADAMs: Targets for Drug Discovery (Executive Editor: Marcia L. Moss)]
Current Pharmaceutical Design Renal Solute Transporters and Their Relevance to Serum Urate Disorder
Current Hypertension Reviews Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Opioid Substitution Therapy: Achieving Harm Reduction While Searching for a Prophylactic Solution
Current Pharmaceutical Biotechnology Gestational Exposure to Serotonin Reuptake Inhibitors and Pregnancy Outcome; Exploring the Role of Bias and Confounders
Current Neuropharmacology The Role of Genes Involved in Neuroplasticity and Neurogenesis in the Observation of a Gene-Environment Interaction (GxE) in Schizophrenia
Current Molecular Medicine Biological Basis of Ageing, Age-related Diseases and Interventions
Current Pharmacogenomics and Personalized Medicine Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Current Pharmaceutical Design IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Monoamino Oxidase A: An Interesting Pharmacological Target for the Development of Multi-Target QSAR
Mini-Reviews in Medicinal Chemistry Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Topics in Medicinal Chemistry Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design